Please login to the form below

Not currently logged in
Email:
Password:

Sylvant

This page shows the latest Sylvant news and features for those working in and with pharma, biotech and healthcare.

EC approves Janssen rare blood disorder drug

EC approves Janssen rare blood disorder drug

EC approves Janssen rare blood disorder drug. Sylvant available to treat multicentric Castleman's disease. ... The European Commission's decision to greenlight Sylvant comes shortly after its April.

Latest news

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castleman’s disease

    FDA approves Janssen drug for rare Castleman’ s disease. Sylvant approved to treat lymphoma-like condition. ... Sylvant is also under review in the EU where Janssen submitted a drug filing in September last year. .

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    EMA backs Janssen rare disease drug for approval. Castleman's disease treatment Sylvant wins CHMP recommendation. ... J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.

  • Boehringer/Lilly's empagliflozin among CHMP recommendations Boehringer/Lilly's empagliflozin among CHMP recommendations

    There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics